Tyruko (natalizumab) was launched in the US in November 2025 as the first and only multiple-sclerosis biosimilar, approved for all indications of the reference medicine
Biological agents: Many biologics used to treat chronic diseases use fillable syringes for easy operation by patients or medical personnel, such as multiple sclerosis, infertility, osteoporosis, hepatitis, rheumatoid arthritis, cancer, anemia, and hemophilia
O uso da semaglutida oral para o tratamento da obesidade foi avaliada no estudo clnico OASIS 1 (Efficacy and Safety of Oral Semaglutide 50 mg Once Daily in Subjects With Overweight or Obesity), o qual demonstrou eficcia na dose de 50mg diria prxima a da semalgutida subcutnea na dose de 2,4mg semanal, porm seu uso ainda no est aprovado em bula para pacientes no diabticos
Overall, Adderall and Vyvanse are both effective at treating ADHD in children and adults and are generally well-tolerated, even up to daily doses of 70 mg